Abstract 638
Background
Misdiagnosis of soft tissue sarcoma (STS) is common, due to their rarity and unclear clinical presentation. As a result, unplanned excisions (UE) may occur, most often necessitating further treatment at specialised tumour centres. Therapy includes re-resection and adjuvant radiotherapy (ARTX), being associated with increased morbidity. Results on UE’s impact on overall survival (OS) are contradictory, though.
Methods
728 STS patients (376 male, 352 female; mean age: 58 years) undergoing primary surgery or re-resection following UE at three tumour centres were retrospectively included. Median follow-up was 5.5 years. Differences between UE- and non-UE-patients were analysed using chi-square and t-tests. Log-rank and Gray’s tests were applied for time-to-event analyses. Based on differences between UE- and non-UE-patients at baseline, a propensity score of being in the UE-group was estimated. Based on the propensity score, an inverse-probability-of-UE-weight (IPUEW) was calculated. This allowed re-calculation of time-to-event analyses following adjustment for imbalances between non-UE- and UE-patients.
Results
UE had been performed in 281 patients (38.6%), with similar incidences at the three tumour centres. Small (p < 0.005) and superficially located STS (p < 0.005) with a long history of symptoms (p < 0.005), male gender (p = 0.05) and young age (p = 0.036) raised the risk of an UE being performed. At re-resection, plastic reconstruction (p < 0.005) and ARTX (p = 0.041) were significantly more common in UE-patients. In the univariate analysis, UE-patients had a significantly better OS (5-/10-year OS: 78.6%/63.3% for UE; 70.6%/57.9% for non-UE; p = 0.028). Due to a strong correlation between positive prognostic factors and a prior UE, survival analyses were re-calculated after weighting for the IPUEW. As a result, the prognostic benefit of UE in terms of OS was lost (p = 0.241).
Conclusions
Morbidity is raised in patients following UE due to increased necessity of plastic reconstruction and ARTX. However, there is no direct impact of UE on OS. Nevertheless, it is arguable whether a more aggressive approach in the UE-group compensates for the inappropriate primary resection. Thus, UE must be avoided by all means.
Clinical trial identification
Legal entity responsible for the study
Medical University of Graz.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4221 - Natural history of sarcomas and impact of reference centers in the nationwide NETSARC study on 35,784 patients (pts) from 2010 to 2017.
Presenter: Jean-Yves Blay
Session: Proffered paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
983 - A phase II/III trial of hafnium oxide nanoparticles activated by radiotherapy in the treatment of locally advance soft tissue sarcoma of the extremity and trunk wall
Presenter: Sylvie Bonvalot
Session: Proffered paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
Proffered paper session - Sarcoma - Invited Discussant 1601O, 1602O and LBA66
Presenter: Rick L. Haas
Session: Proffered paper session - Sarcoma
Resources:
Slides
Webcast
4816 - Initial Results of Phase 1 Study of DCC-2618, a Broad-spectrum KIT and PDGFRa Inhibitor, in Patients (pts) with Gastrointestinal Stromal Tumor (GIST) by Number of Prior Regimens.
Presenter: Suzanne George
Session: Proffered paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
6067 - Cabozantinib in Patients With Advanced Osteosarcomas and Ewing sarcomas: a French Sarcoma Group (FSG)/ US National Cancer Institute phase II collaborative study.
Presenter: Antoine Italiano
Session: Proffered paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
Proffered paper session - Sarcoma - Invited Discussant 1603O and LBA67
Presenter: Daniela Katz
Session: Proffered paper session - Sarcoma
Resources:
Slides
Webcast